Massachusetts Institute of Technology

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia

As the improvements made possible with artificial intelligence and machine learning for biopharmaceutical research and development become clear, deal making in the space has skyrocketed. S&P Global pr

Two RNA technology specialists created by venture capital investor MPM BioImpact and launched with large amounts of money to pursue their ambitious ideas will bring their shared economic interests und

The quarterly Venture Monitor report from Pitchbook and the National Venture Capital Association (NVCA) reported biopharma start-ups raised $5.9bn in the first quarter of 2024 – more than the sector r